Lamtor5/cgas-targeting peptide
Lamtor5/cgas-targeting peptide has been studied in 1 paper since 2026: none in people yet, 1 in animals; 1 in the past year. The research so far is in animals. The newest paper, Jul 16, 2026: “Age-associated decline of Lamtor5 drives immunosenescence and systemic aging via cGAS-mediated paracrine inflammation”.
1 paper studies it1 findingUpdated
- 1 lab in 1 country
- Funder: National Natural Science Foundation of China
- Animals1
What did studies of Lamtor5/cgas-targeting peptide find?
1Studies of Lamtor5/cgas-targeting peptide measured 1 outcome; the most studied are tissue dysfunction (1 study).
Tissue dysfunction
downin mice1
1 study
Tissue dysfunction
downin mice1
Lamtor5/cgas-targeting peptide decreases tissue dysfunction in mice.
“a small peptide targeting the Lamtor5/cGAS interface profoundly alleviated aging-associated inflammation and tissue dysfunction in aged mice”
Animalsin aged mice
Cell death and differentiation
Latest
1 paper in 12 monthsCell Death and Differentiation
Age-associated decline of Lamtor5 drives immunosenescence and systemic aging via cGAS-mediated paracrine inflammation
Experiments in miceInterventions